Allander Biotechnologies

Funding and NIH signals

• NIH award NIH awarded $1.21M (SBIR Phase II 1R44DE034643-01A1, new, notice Sep 17, 2026); 2 NIH awards totaling $2.28M in the last 12 months. NIH RePORTER 1R44DE034643-01A1 (Sep 17, 2026)
  Evidence (2 events)

  • Sep 17, 2026 · NIH RePORTER 1R44DE034643-01A1
    Organization: ALLANDER BIOTECHNOLOGIES, INC.; City/State: AURORA, CO; Project number: 1R44DE034643-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1210798; Administering IC: National Institute of Dental and Craniofacial Research; Project title: cGMP manufacturing the clinical batch of oral gel drug for treating oral mucositis in cancer patients; Organization type: Domestic For-Profits
  • Sep 14, 2026 · NIH RePORTER 5R44CA310522-02
    Organization: ALLANDER BIOTECHNOLOGIES, INC.; City/State: AURORA, CO; Project number: 5R44CA310522-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1066148; Administering IC: National Cancer Institute; Project title: First-in-human clinical trial of proprietary oral gel to treat radiation-induced oral mucositis in cancer patients; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals